Activity of the novel BCR kinase inhibitor IQS019 in preclinical models of B-cell non-Hodgkin lymphoma

Activity of the novel BCR kinase inhibitor IQS019 in preclinical models of B-cell non-Hodgkin lymphoma

Abstract Background Pharmacological inhibition of B cell receptor (BCR) signaling has recently emerged as an effective approach in a wide range of B lymphoid neoplasms. However, despite promising clinical activity of the first Bruton’s kinase (Btk) and spleen tyrosine kinase (Syk) inhibitors, a smal...

Full description

Bibliographic Details
Main Authors: P. Balsas, A. Esteve-Arenys, J. Roldán, L. Jiménez, V. Rodríguez, J. G. Valero, A. Chamorro-Jorganes, R. Puig de la Bellacasa, J. Teixidó, A. Matas-Céspedes, A. Moros, A. Martínez, E. Campo, A. Sáez-Borderías, J. I. Borrell, P. Pérez-Galán, D. Colomer, G. Roué
Format: Article
Language:English
Published: BMC 2017-03-01
Series:Journal of Hematology & Oncology
Subjects:
B-NHL
Btk
Lyn
Syk
Cell migration
Mouse model
Online Access:http://link.springer.com/article/10.1186/s13045-017-0447-6

Similar Items

Similar Items